| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-11 10:44:51 UTC |
|---|
| Update Date | 2021-09-26 23:05:31 UTC |
|---|
| HMDB ID | HMDB0252732 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | Givinostat |
|---|
| Description | Givinostat belongs to the class of organic compounds known as phenylcarbamic acid esters. These are ester derivatives of phenylcarbamic acids. Givinostat inhibits class I and class II histone deacetylases (HDACs) and several pro-inflammatory cytokines. Givinostat is a very strong basic compound (based on its pKa). In patients with polycythaemia, the reduction of mutant JAK2 concentrations by givinostat is believed to slow down the abnormal growth of erythrocytes and ameliorate the symptoms of the disease. One-fifth of patients experienced prolongation of the QT interval, a measure of electrical conduction in the heart, severe enough to warrant temporary suspension of treatment. In clinical trials of givinostat as a salvage therapy for advanced Hodgkin's lymphoma, the most common adverse reactions were fatigue (seen in 50% of participants), mild diarrhea or abdominal pain (40% of participants), moderate thrombocytopenia (decreased platelet counts, seen in one third of patients), and mild leukopenia (a decrease in white blood cell levels, seen in 30% of patients). Givinostat is in numerous phase II clinical trials (including for relapsed leukemias and myelomas), and has been granted orphan drug designation in the European Union for the treatment of systemic juvenile idiopathic arthritis, polycythaemia vera. This reduces expression of tumour necrosis factor (TNF), interleukin 1α and β, and interleukin 6. A preclinical study produced early results suggesting the molecule might help with diastolic dysfunction. It is a hydroxamate used in the form of its hydrochloride. ITF2357 was discovered at Italfarmaco of Milan, Italy. It was patented in 1997 and first described in the scientific literature in 2005. Givinostat (INN) or gavinostat (originally ITF2357) is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It also has activity against cells expressing JAK2(V617F), a mutated form of the janus kinase 2 (JAK2) enzyme that is implicated in the pathophysiology of many myeloproliferative diseases, including polycythaemia vera. This compound has been identified in human blood as reported by (PMID: 31557052 ). Givinostat is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Givinostat is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | CCN(CC)CC1=CC=C2C=C(COC(=O)NC3=CC=C(C=C3)C(=O)NO)C=CC2=C1 InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28) |
|---|
| Synonyms | Not Available |
|---|
| Chemical Formula | C24H27N3O4 |
|---|
| Average Molecular Weight | 421.497 |
|---|
| Monoisotopic Molecular Weight | 421.200156361 |
|---|
| IUPAC Name | {6-[(diethylamino)methyl]naphthalen-2-yl}methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate |
|---|
| Traditional Name | givinostat |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CCN(CC)CC1=CC=C2C=C(COC(=O)NC3=CC=C(C=C3)C(=O)NO)C=CC2=C1 |
|---|
| InChI Identifier | InChI=1S/C24H27N3O4/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28) |
|---|
| InChI Key | YALNUENQHAQXEA-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenylcarbamic acid esters. These are ester derivatives of phenylcarbamic acids. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Phenylcarbamic acid esters |
|---|
| Direct Parent | Phenylcarbamic acid esters |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenylcarbamic acid ester
- Naphthalene
- Benzoic acid or derivatives
- Benzoyl
- Aralkylamine
- Carbamic acid ester
- Amino acid or derivatives
- Hydroxamic acid
- Tertiary aliphatic amine
- Tertiary amine
- Carbonic acid derivative
- Carboxylic acid derivative
- Amine
- Organonitrogen compound
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Carbonyl group
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Aromatic homopolycyclic compound
|
|---|
| Molecular Framework | Aromatic homopolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Predicted by Siyang on May 30, 2022 | 10.233 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.53 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1510.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 178.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 166.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 167.9 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 61.9 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 341.8 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 413.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 252.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 646.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 403.7 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1260.4 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 223.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 311.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 269.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 274.9 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 60.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Givinostat,1TMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)NO)C=C3)[Si](C)(C)C)C=CC2=C1 | 3926.4 | Semi standard non polar | 33892256 | | Givinostat,1TMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)NO)C=C3)[Si](C)(C)C)C=CC2=C1 | 3717.2 | Standard non polar | 33892256 | | Givinostat,1TMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)NO)C=C3)[Si](C)(C)C)C=CC2=C1 | 4822.3 | Standard polar | 33892256 | | Givinostat,1TMS,isomer #2 | CCN(CC)CC1=CC=C2C=C(COC(=O)NC3=CC=C(C(=O)N(O)[Si](C)(C)C)C=C3)C=CC2=C1 | 3979.0 | Semi standard non polar | 33892256 | | Givinostat,1TMS,isomer #2 | CCN(CC)CC1=CC=C2C=C(COC(=O)NC3=CC=C(C(=O)N(O)[Si](C)(C)C)C=C3)C=CC2=C1 | 3749.3 | Standard non polar | 33892256 | | Givinostat,1TMS,isomer #2 | CCN(CC)CC1=CC=C2C=C(COC(=O)NC3=CC=C(C(=O)N(O)[Si](C)(C)C)C=C3)C=CC2=C1 | 5009.8 | Standard polar | 33892256 | | Givinostat,2TMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)N(O)[Si](C)(C)C)C=C3)[Si](C)(C)C)C=CC2=C1 | 3749.8 | Semi standard non polar | 33892256 | | Givinostat,2TMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)N(O)[Si](C)(C)C)C=C3)[Si](C)(C)C)C=CC2=C1 | 3546.0 | Standard non polar | 33892256 | | Givinostat,2TMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)N(O)[Si](C)(C)C)C=C3)[Si](C)(C)C)C=CC2=C1 | 4581.5 | Standard polar | 33892256 | | Givinostat,1TBDMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)NO)C=C3)[Si](C)(C)C(C)(C)C)C=CC2=C1 | 4189.6 | Semi standard non polar | 33892256 | | Givinostat,1TBDMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)NO)C=C3)[Si](C)(C)C(C)(C)C)C=CC2=C1 | 3897.9 | Standard non polar | 33892256 | | Givinostat,1TBDMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)NO)C=C3)[Si](C)(C)C(C)(C)C)C=CC2=C1 | 4797.1 | Standard polar | 33892256 | | Givinostat,1TBDMS,isomer #2 | CCN(CC)CC1=CC=C2C=C(COC(=O)NC3=CC=C(C(=O)N(O)[Si](C)(C)C(C)(C)C)C=C3)C=CC2=C1 | 4240.4 | Semi standard non polar | 33892256 | | Givinostat,1TBDMS,isomer #2 | CCN(CC)CC1=CC=C2C=C(COC(=O)NC3=CC=C(C(=O)N(O)[Si](C)(C)C(C)(C)C)C=C3)C=CC2=C1 | 3920.9 | Standard non polar | 33892256 | | Givinostat,1TBDMS,isomer #2 | CCN(CC)CC1=CC=C2C=C(COC(=O)NC3=CC=C(C(=O)N(O)[Si](C)(C)C(C)(C)C)C=C3)C=CC2=C1 | 4983.0 | Standard polar | 33892256 | | Givinostat,2TBDMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)N(O)[Si](C)(C)C(C)(C)C)C=C3)[Si](C)(C)C(C)(C)C)C=CC2=C1 | 4253.9 | Semi standard non polar | 33892256 | | Givinostat,2TBDMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)N(O)[Si](C)(C)C(C)(C)C)C=C3)[Si](C)(C)C(C)(C)C)C=CC2=C1 | 3885.1 | Standard non polar | 33892256 | | Givinostat,2TBDMS,isomer #1 | CCN(CC)CC1=CC=C2C=C(COC(=O)N(C3=CC=C(C(=O)N(O)[Si](C)(C)C(C)(C)C)C=C3)[Si](C)(C)C(C)(C)C)C=CC2=C1 | 4624.9 | Standard polar | 33892256 |
|
|---|